EUVIMEDEUVIMED entdecken
Kohortenstudie

TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study

Taha Alam, Zeyad Kholeif, Sohaima Kamal, Muhammad Hussain, Muhammad Salman Mustafa, Asad Zaman, Abdul basit, Muhammad Hassan, Noor Un Nisa, Meet Popatbhai Kachhadia, Muhammad Talha Usman, Hammad Khan und 1 weitere

JACC · 2026-11 · 88 (18) · B7-B8

DOI: 10.1016/j.jacc.2026.09.059 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift JACC, 2026-11. Verfasst von Taha Alam und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Alam, T., Kholeif, Z., Kamal, S., Hussain, M., Mustafa, M. S., Zaman, A., basit, A., Hassan, M., Nisa, N. U., Kachhadia, M. P., Usman, M. T., Khan, H., & Ahamed, M. S. I. (2026). TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study. JACC, 88(18), B7-B8. https://doi.org/10.1016/j.jacc.2026.09.059

Vancouver

Alam T, Kholeif Z, Kamal S, Hussain M, Mustafa MS, Zaman A, et al. TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study. JACC. 2026;88(18):B7-B8. doi:10.1016/j.jacc.2026.09.059

BibTeX
@article{Alam2026,
  author = {Alam, Taha and Kholeif, Zeyad and Kamal, Sohaima and Hussain, Muhammad and Mustafa, Muhammad Salman and Zaman, Asad and basit, Abdul and Hassan, Muhammad and Nisa, Noor Un and Kachhadia, Meet Popatbhai and Usman, Muhammad Talha and Khan, Hammad and Ahamed, Mohamed Shabbeer Imtiaz},
  title = {TCT-18 Real-World Comparative Outcomes of Tirzepatide and Dulaglutide in Adults With Type 2 Diabetes Mellitus: A TriNetX Propensity Score–Matched Cohort Study},
  journal = {JACC},
  year = {2026},
  volume = {88},
  number = {18},
  pages = {B7--B8},
  doi = {10.1016/j.jacc.2026.09.059}
}
Kostenlos starten →